Drug labels

Scholars and practitioners debate whether and how to regulate off-label drug use.

Scholar argues that FDA approval should not save drug makers from state-law claims arising from off-label use.

Scholar argues that FDA should adopt an evidenced-based approach to regulating drug manufacturers’ speech.

Two scholars find that the removal of FDA health warnings prompts an increase in drug marketing.